Bristol-Myers Squibb Posts Data Update on BMS-790052, an NS5A Inhibitor in Phase 2 Development for the Treatment of Hepatitis C

Bristol-Myers Squibb Posts Data Update on BMS-790052, an NS5A Inhibitor in Phase 2 Development for the Treatment of Hepatitis C

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today posted an overview of new data on BMS-790052 on the company website, available here. BMS-790052 is an NS5A inhibitor in Phase 2 development for the treatment of hepatitis C. The data were presented today at the European Association for the Study of the Liver (EASL) meeting in Vienna.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.